Some psychedelic drugs could soon be approved by the FDA
The US Food and Drug Administration issued national priority vouchers to companies studying psilocybin and methylone for the treatment of some mental health disorders. The vouchers were granted under a pilot program launched last year as a way to fast-track the review process for certain drugs seeking approval, potentially speeding up the time it takes for them to reach patients.
